The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a broad range of clinical responses including prominent microvascular damage. The capacity of SARS-CoV-2 to infect vascular cells is still debated. Additionally, the SARS-CoV-2 Spike (S) protein may act as a ligand to induce non-infective cellular stress. We tested this hypothesis in pericytes (PCs), which are reportedly reduced in the heart of patients with severe coronavirus disease-2019 (COVID-19). Here we newly show that the in vitro exposure of primary human cardiac PCs to the SARS-CoV-2 wildtype strain or the α and δ variants caused rare infection events. Exposure to the recombinant S protein alone elicited signalling and functional alterations, including: (1) increased migration, (2) reduced ability to support endothelial cell (EC) network formation on Matrigel, (3) secretion of pro-inflammatory molecules typically involved in the cytokine storm, and (4) production of pro-apoptotic factors causing EC death. Next, adopting a blocking strategy against the S protein receptors angiotensin-converting enzyme 2 (ACE2) and CD147, we discovered that the S protein stimulates the phosphorylation/activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) through the CD147 receptor, but not ACE2, in PCs. The neutralisation of CD147, either using a blocking antibody or mRNA silencing, reduced ERK1/2 activation, and rescued PC function in the presence of the S protein. Immunoreactive S protein was detected in the peripheral blood of infected patients. In conclusion, our findings suggest that the S protein may prompt PC dysfunction, potentially contributing to microvascular injury. This mechanism may have clinical and therapeutic implications.


    1. Lowenstein C.J. and Solomon S.D. (2020) Severe COVID-19 is a microvascular disease. Circulation 142, 1609–1611 10.1161/CIRCULATIONAHA.120.050354 – DOI – PMC – PubMed
    1. Ostergaard L. (2021) SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol. Rep. 9, e14726 10.14814/phy2.14726 – DOI – PMC – PubMed
    1. Yin al. . (2021) Coronary microvascular dysfunction pathophysiology in COVID-19. Microcirculation 28(7), e12718 10.1111/micc.12718 – DOI – PMC – PubMed
    1. Argenziano al. . (2020) Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ 369, m1996 10.1136/bmj.m1996 – DOI – PMC – PubMed
    1. Verity al. . (2020) Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect. Dis. 6, 669–677 10.1016/S1473-3099(20)30243-7 – DOI – PMC – PubMed